Bilyana Stoilova
PhD, MSc, BSc
Senior Programme Manager
I joined OVG in December 2021 as a Project manager to ensure that the clinical trials are delivered on time, within budget and in compliance with the regulatory requirements. I manage the set up and delivery of non-commercial and commercial, University of Oxford- or externally-sponsored, adult and paediatric vaccine clinical trials.
Before joining OVG, from 2008 till 2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany.
After completing my PhD, I worked as a postdoctoral researcher at Prof Paresh Vyas research group Biology and Treatment of Human Myeloid Cancers at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. I worked on research projects aiming to understand the mechanisms of blood cell development and how these mechanisms get deregulated in leukaemia.
Recent publications
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Journal article
Turkalj S. et al, (2026), Blood, 147, 613 - 632
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy
Preprint
Turkalj S. et al, (2024)
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Journal article
Aksöz M. et al, (2024), Sci Immunol, 9
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Journal article
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)